Award of NHS Framework for North of England Branded Medicines (Tranche A & Annual Tranche) and Risankizumab Supply

About

NHS England awarded a contract to Roche Products Ltd, Sandoz Ltd, Teva UK Limited, Celltrion Healthcare United Kingdom Limited, Merck Sharpe & Dohme (UK) Limited, Chugai Pharma UK Ltd, Amgen Ltd, Janssen-Cilag Ltd, Accord-UK Ltd, Pfizer Ltd, and others for the NHS Framework for North of England Branded Medicines, comprising Tranche A and the Annual Tranche, as well as the NHS National Framework Agreement for the supply of Risankizumab for South of England and London.

The contract value is £261,970,000.

The framework periods are: Tranche A from 1 March 2023 to 28 February 2025 with extension options up to 24 months; Annual Tranche from 1 March 2023 to 29 February 2024 with extension options up to 12 months; and Risankizumab supply from 1 March 2023 to 31 August 2023 with extension options up to 6 months.